Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21283183 | 0.78 | ERN1 (0.64) | ERN1 | |
| SCHEMBL20670785 | 0.78 | ERN1 (0.44) | ERN1 | |
| SCHEMBL585592 | 0.76 | ERN1 (0.61) | ERN1CES2CES1 | |
| SCHEMBL295466 | 0.75 | ERN1 (0.43) | ERN1CES2CES1 | |
| SCHEMBL2938544 | 0.74 | CES2 (0.41) | CES2CES1 | |
| SCHEMBL27185645 | 0.74 | ERN1 (0.53) | ERN1 | |
| SCHEMBL8255062 | 0.74 | ALDH1A1 (0.47) | ERN1MCL1 | |
| SCHEMBL14302789 | 0.73 | ERN1 (0.37) | ERN1 | |
| SCHEMBL20798249 | 0.73 | ERN1 (0.52) | ERN1 | |
| SCHEMBL21949881 | 0.73 | ERN1 (0.38) | ERN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20100261719-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| EP-2193132-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009004382-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | ERN1 82/4885MCL1 3719/4885CES2 1135/4885 |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | ERN1 82/4885MCL1 3719/4885CES2 1135/4885 |
| US-20100261719-A1 | CHEMICAL COMPOUNDS | NCOA3, NR4A3, NR0B2 | ERN1 1745/4885MCL1 2195/4885CES2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.